BioWorld

March 1, 2010

IPO Activity Poised to Pop with Anthera, Aveo and Trius on Deck

It's been nearly a month since Ironwood Pharmaceuticals Inc. tested the biotech initial public offering waters, and now three more biotechs are queued up to price IPOs over the next three weeks. (BioWorld Today) Read More

HCV Combo Approach Keeping Partner Hopes Bright for Idenix

'Clear and Testable Hypothesis' on Pediatric Asthma's Roots

Amicus Adds $18.5M Publicly for Phase III Amigal Program

Collins: NIH Funding Boosts Economy, Spurs Job Growth

Move Over, Cerezyme; Shire's Vpriv Gets Official FDA Nod

Other News To Note

Vital Signs for March 1, 2010

Clinic Roundup

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...